Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Epidemiological impact of a genital herpes type 2 vaccine for young females.

Lou Y, Qesmi R, Wang Q, Steben M, Wu J, Heffernan JM.

PLoS One. 2012;7(10):e46027. doi: 10.1371/journal.pone.0046027. Epub 2012 Oct 11.

2.

The potential epidemiological impact of a genital herpes vaccine for women.

Garnett GP, Dubin G, Slaoui M, Darcis T.

Sex Transm Infect. 2004 Feb;80(1):24-9.

3.

Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.

Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM Jr, Handsfield HH, Warren T, Marr L, Tyring S, DiCarlo R, Adimora AA, Leone P, Dekker CL, Burke RL, Leong WP, Straus SE.

JAMA. 1999 Jul 28;282(4):331-40.

PMID:
10432030
4.

Herpes simplex virus type 2 in Brazil: seroepidemiologic survey.

Da Rosa-Santos OL, Gonçalves Da Silva A, Pereira AC Jr.

Int J Dermatol. 1996 Nov;35(11):794-6.

PMID:
8915732
5.

Genital herpes infection: a review.

Brugha R, Keersmaekers K, Renton A, Meheus A.

Int J Epidemiol. 1997 Aug;26(4):698-709. Review.

6.

Efficacy results of a trial of a herpes simplex vaccine.

Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, Gorfinkel I, Morrow RL, Ewell MG, Stokes-Riner A, Dubin G, Heineman TC, Schulte JM, Deal CD; Herpevac Trial for Women.

N Engl J Med. 2012 Jan 5;366(1):34-43. doi: 10.1056/NEJMoa1103151.

7.

Glycoprotein-D-adjuvant vaccine to prevent genital herpes.

Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, Tyring S, Aoki FY, Slaoui M, Denis M, Vandepapeliere P, Dubin G; GlaxoSmithKline Herpes Vaccine Efficacy Study Group.

N Engl J Med. 2002 Nov 21;347(21):1652-61.

8.

Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.

HSV-040 Study Group, Abu-Elyazeed RR, Heineman T, Dubin G, Fourneau M, Leroux-Roels I, Leroux-Roels G, Richardus JH, Ostergaard L, Diez-Domingo J, Poder A, Van Damme P, Romanowski B, Blatter M, Silfverdal SA, Berglund J, Josefsson A, Cunningham AL, Flodmark CE, Tragiannidis A, Dobson S, Olafsson J, Puig-Barbera J, Mendez M, Barton S, Bernstein D, Mares J, Ratner P.

Vaccine. 2013 Dec 9;31(51):6136-43. doi: 10.1016/j.vaccine.2013.06.081. Epub 2013 Jul 9.

PMID:
23850416
10.
11.

Reducing the risk of transmitting genital herpes: advances in understanding and therapy.

Leone P.

Curr Med Res Opin. 2005 Oct;21(10):1577-82. Review.

PMID:
16238897
12.

Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease.

Jones CA, Cunningham AL.

Herpes. 2004 Apr;11(1):12-7. Review.

PMID:
15115632
13.

Seroprevalence and risk factors of herpes simplex virus type-2 infection among pregnant women in Northeast India.

Biswas D, Borkakoty B, Mahanta J, Walia K, Saikia L, Akoijam BS, Jampa L, Kharkongar A, Zomawia E.

BMC Infect Dis. 2011 Nov 23;11:325. doi: 10.1186/1471-2334-11-325.

14.
15.

Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.

Stanberry LR.

Herpes. 2004 Aug;11 Suppl 3:161A-169A. Review.

PMID:
15319086
16.

A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease.

Boursnell ME, Entwisle C, Blakeley D, Roberts C, Duncan IA, Chisholm SE, Martin GM, Jennings R, Ni Challanaín D, Sobek I, Inglis SC, McLean CS.

J Infect Dis. 1997 Jan;175(1):16-25.

17.

Prevalence and risk factors for herpes simplex virus type 2 antibodies among low- and high-risk populations in Indonesia.

Davies SC, Taylor JA, Sedyaningsih-Mamahit ER, Gunawan S, Cunningham AL, Mindel A.

Sex Transm Dis. 2007 Mar;34(3):132-8.

PMID:
16868530
18.

Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2.

Alsallaq RA, Schiffer JT, Longini IM Jr, Wald A, Corey L, Abu-Raddad LJ.

Sex Transm Dis. 2010 May;37(5):290-7. doi: 10.1097/OLQ.0b013e3181d3d023.

19.

Herpes simplex virus-2 infection. An emerging disease?

Schomogyi M, Wald A, Corey L.

Infect Dis Clin North Am. 1998 Mar;12(1):47-61. Review.

PMID:
9494829
20.

A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections.

Chiuppesi F, Vannucci L, De Luca A, Lai M, Matteoli B, Freer G, Manservigi R, Ceccherini-Nelli L, Maggi F, Bendinelli M, Pistello M.

J Virol. 2012 Jun;86(12):6563-74. doi: 10.1128/JVI.00302-12. Epub 2012 Apr 4.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk